Table 3.
Sociodemographic Factors Felated to the use of Colorectal Cancer Screening Tests per US Preventive Services Task Force Guideline
| FOBT N(%) |
Sigmoidoscopy + FOBT N(%) |
Colonoscopy N(%) |
CRC Screening Adherence N(%) |
|
|---|---|---|---|---|
| Site | ||||
| Clinic 1 | 148 (24.5%)** | 16 (2.6%) | 132 (21.9%) | 254 (42.1%) |
| Clinic 2 | 69 (16.7%) | 6 (1.5%) | 106 (25.7%) | 164 (39.8%) |
| Age | ||||
| 50–64 | 158 (21.8%) | 14 (1.9%) | 156 (21.5%)* | 290 (40%) |
| 65+ | 59 (20.3%) | 8 (2.7%) | 82 (28.2%) | 128 (44%) |
| Gender | ||||
| Female | 167 (24.4%)** | 15 (2.2%) | 162 (23.7%) | 299 (43.7%)* |
| Male | 50 (15.1%) | 7 (2.1%) | 76 (22.9%) | 119 (35.8%) |
| Insurance Status | ||||
| None | 21 (14.6%)** | 1 (0.7%) | 9 (6.3%)** | 29 (20.1%)** |
| Public | 169 (24.2%) | 16 (2.3%) | 185 (26.5%) | 320 (45.8%) |
| Private | 27 (15.5%) | 5 (2.9%) | 44 (25.3%) | 69 (39.7%) |
| Continuity Index | ||||
| 1 Visit | 7 (8.4%)** | 1 (1.2%) | 7 (8.4%)** | 13 (15.7%)** |
| Lower | 153 (23.3%) | 17 (2.6%) | 163 (24.8%) | 287 (43.6%) |
| Higher | 57 (20.7%) | 4 (1.5%) | 68 (24.7%) | 118 (42.9%) |
| Charlson-Deyo Comorbidity Score | ||||
| 0 | 154 (21.4%) | 14 (1.9%) | 165 (22.9%) | 289 (40.1%) |
| 1 | 51 (23.2%) | 6 (2.7%) | 49 (22.3%) | 95 (43.2%) |
| ≥ 2 | 12 (15.8%) | 2 (2.6%) | 24 (31.6%) | 34 (44.7%) |
| Primary Care Provider | ||||
| None | 2 (11.1%) | 0 (0%) | 2 (11.1%) | 3 (16.7%)* |
| MD | 120 (20.6%) | 17 (2.9%) | 152 (26.1%) | 251 (43.1%) |
| PA/ARNP | 95 (22.8%) | 5 (1.2%) | 84 (20.2%) | 164 (39.4%) |
| Language Concordant PCP | ||||
| None | 2 (11.1%) | 0 (0%) | 2 (11.1%) | 3 (16.7%) |
| No | 115 (22.7%) | 11 (2.2%) | 124 (24.5%) | 217 (42.9%) |
| Yes | 100 (20.3%) | 11 (2.2%) | 112 (22.8%) | 198 (40.2%) |
*
p = < 0.05,
**
p = < 0.01;
ARNP = nurse practitioner; CRC = colorectal cancer; FOBT = fecal occult blood test; MD = physician; PA = physician assistant; PCP = primary care provider